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Glycogen synthase (GS), a key enzyme in glycogen
synthesis, is activated by the allosteric stimulator
glucose-6-phosphate (G6P) and by dephosphoryla-
tion through inactivation of GS kinase-3 with insulin.
The relative importance of these two regulatory
mechanisms in controlling GS is not established,
mainly due to the complex interplay between
multiple phosphorylation sites and allosteric effec-
tors. Here we identify a residue that plays an impor-
tant role in the allosteric activation of GS by G6P.
We generated knockin mice in which wild-type
muscle GS was replaced by a mutant that could not
be activated by G6P but could still be activated
normally by dephosphorylation. We demonstrate
that knockin mice expressing the G6P-insensitive
mutant display an 80% reduced muscle glycogen
synthesis by insulin and markedly reduced glycogen
levels. Our study provides genetic evidence that allo-
steric activation of GS is the primary mechanism by
which insulin promotes muscle glycogen accumula-
tion in vivo.
INTRODUCTION
Elevated blood glucose levels after a meal are rapidly returned to
normal, and during starvation blood glucose is maintained only
slightly below normal. Such a sophisticated control system is
essential to prevent serious dysfunctions such as loss of
consciousness due to hypoglycaemia and toxicity to peripheral
tissues in response to persistent hyperglycaemia (Wasserman,
2009). Glucose is distributed into multiple tissues of the body
where it can be oxidized to produce energy or stored as the poly-
saccharide glycogen. In humans, the major cellular mechanism
for disposal of ingested glucose is insulin-stimulated glucose
transport into skeletal muscle, with the majority of glucose that
enters muscle fibers being converted to glycogen (Shulman
et al., 1990). Therefore, impaired insulin-stimulated muscle
glucose transport and glycogen synthesis are implicated in the456 Cell Metabolism 12, 456–466, November 3, 2010 ª2010 Elsevierpathogenesis of insulin resistance and type 2 diabetes (Shulman,
2000).
Insulin stimulates glucose transport by promoting the translo-
cation of the glucose transporter, GLUT4, from intracellular
compartments to the cell surface. The resulting increase in
glucose transport and phosphorylation of glucose by hexokinase
leads to an increase in the intracellular concentration of glucose-
6-phosphate (G6P). G6P is mainly used for the synthesis of
glycogen in resting muscle, while it is largely metabolized in
the glycolytic pathway during contraction. During glycogen
synthesis, G6P is converted to UDP-glucose and the glucosyl
unit from UDP-glucose is used to elongate a nascent glycogen
chain through a-1,4-glycosidic bonds by the action of glycogen
synthase (GS), which is stimulated by insulin (Roach, 2002). This
activation of GS in response to insulin occurs in minutes and was
the first example of regulation of a specific enzyme by insulin in
cells (Villar-Palasi and Larner, 1960). Despite decades of inten-
sive research in this field, the molecular mechanism(s) whereby
insulin activates GS in vivo is controversial, although several
models have been proposed (Lawrence and Roach, 1997).
In the early 1960s two mechanisms were identified by which
GS activity could be regulated: allosteric activation by G6P
(Leloir et al., 1959) and covalent phosphorylation (Friedman
and Larner, 1963), which inhibits the enzyme. Insulin activates
GS through allosteric regulation by elevating the levels of G6P
via glucose transport and also phospho-dependentmechanisms
by promoting the conversion of GS from a highly phosphorylated
(low-activity) form to a less phosphorylated (high-activity) form
through the protein kinase B (PKB, also known as Akt)-depen-
dent inactivation of glycogen synthase kinase 3 (GSK3) (McMa-
nus et al., 2005). Dephosphorylation results in significant
changes in the kinetic properties of GS, decreasing the Km for
the substrate UDP-glucose and the A0.5 for G6P (Friedman and
Larner, 1963; Jensen and Lai, 2009). Thus, it is thought that
insulin stimulates GS through the complex interplay between
phosphorylation and allosteric regulation. A major obstacle to
gaining molecular insight into how insulin regulates GS in vivo
is a lack of understanding of the relative importance of these
two regulatory mechanisms, allosteric and phospho dependent,
in controlling GS activity.
To understand the contribution that phospho-dependent acti-
vation of GS plays in insulin-stimulated muscle glycogen
synthesis, we previously generated knockin mice expressingInc.
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Figure 1. Mutagenesis and Biochemical Analyses to Identify
Glucose-6 Phosphate-Insensitive Glycogen Synthase Mutants
(A) Amino acid sequence alignment of putative G6P sensitizing residues of
mammalian and yeast GS. Arginine (R) residues located in the G6P-sensitizing
region shown in (A) were mutated individually or in combination to either
alanine (A) or glutamic acid (E).
(B) Constructs expressing wild-type and the indicated GS mutants were
cotransfected with GST-tagged glycogenin. Cell extracts were prepared and
equal amounts of protein were immunoblotted with the indicated antibodies
or assayed for GS activity in the presence and absence of 10 mM G6P. The
ERK1/2 kinases were immunoblotted as a loading control. Results are repre-
sentative of two independent experiments.
(C) Equal quantities of purified GS mutants were dephosphorylated in vitro
using PP1g. The PP1 inhibitor microcystin-LR was used as a negative control.
Mock and PP1g-treated GS mutants were assayed for GS activity in the pres-
ence or absence of G6P and immunoblotted to confirm equal loading and
assess the phosphorylation status of GS. Results are representative of two
independent experiments.
Cell Metabolism
Allosteric Regulation of Muscle Glycogen Synthaseconstitutively active mutants of GSK3 (both a and b isoforms) in
which the PKB phosphorylation sites on GSK3a (Ser21) and
GSK3b (Ser9) were substituted by Ala (GSK3a/bS21A/S21A/S9A/S9A)
(McManus et al., 2005). In GSK3a/bS21A/S21A/S9A/S9A animals, we
found that insulin failed to inactivate muscle GSK3 and hence
promoteGSactivation bydephosphorylation. Strikingly, we found
that insulin-stimulated glycogen synthesis and the levels of
glycogen in skeletal muscle were similar between wild-type and
GSK3a/bS21A/S21A/S9A/S9A mice (Bouskila et al., 2008). These
observations led us to hypothesize that the allosteric activation
of GS by G6P plays a major role in glycogen synthesis, which
would compensate for the lack of phospho-dependent activation
of GS by insulin in the GSK3a/bS21A/S21A/S9A/S9Amice.While this is
an attractive hypothesis, no robust cell-based assays or genetic
models are available to establish the in vivo role that allosteric acti-
vation of GS plays in muscle glycogen synthesis.
To this end, we aimed to identify critical residues for the G6P-
mediated allosteric activation of GS, which could be exploited to
generate a knockin mouse expressing a G6P-insensitive GS
mutant. Here we report genetic evidence that the allosteric acti-
vation of GS is the primary mechanism by which insulin
promotes glycogen synthesis in muscle.
RESULTS
Identification of Critical Residue(s) Important
for Allosteric Activation of GS by G6P
Alignment of the sequences of Saccharomyces cerevisiae and
mammalian GS isoforms revealed that there is a highly basic
segment present at the C terminus of both yeast andmammalian
GS (Figure 1A). Pederson et al. performed scanningmutagenesis
analysis using the major Saccharomyces cerevisiae GS isoform,
Gsy2p, and reported that mutation of multiple arginine residues
within this conserved basic segment to alanine blocked the
allosteric activation by G6P (Pederson et al., 2000). They subse-
quentlydemonstrated that correspondingmutationshadasimilar
effect on rabbit muscle GS (GYS1) (Hanashiro and Roach, 2002).
However, ectopic expression of the G6P-resistant rabbit muscle
GS mutant R578A/R579A/R581A (all three of the indicated Arg
residues changed to Ala) in COS-1 cells revealed a reduced
expression level and a markedly higher basal activity when as-
sayed in the absence of G6P relative to the wild-type enzyme
(Hanashiro and Roach, 2002). Substitution of multiple Arg resi-
dues to Ala likely disrupted the three-dimensional structure, re-
sulting in destabilization and dysfunction of the enzyme. In the
current study, our initial goal was to identify a G6P-insensitive
muscle GS mutant that expressed at normal levels in cells and
alsodisplayedunalteredphospho-dependent activity.Wegener-
ated a series of mutants in which individual Arg residues or
acombinationof twoor threeArg residues in thehighly conserved
basic segment (Figure 1A) were changed to Ala or Glu. We trans-
fected HEK293 cells, which express only trace amounts of
endogenous GS (Figure 1B), with these GS mutants together
with glycogenin, a specialized initiator protein in glycogenesis
which binds to and enhances expression of soluble GS (Skurat
et al., 1993). Thirty-six hours following transfection of these
mutants, cell extracts were generated, and expression of GS
and glycogenin, as well as GS activity, was assessed (Figure 1B).
Consistent with a previous report (Hanashiro and Roach, 2002),Cell Mwe observed that the R579A/R580A/R582A triple mutant was
insensitive to G6P and had modestly reduced expression
compared to the wild-type enzyme. We also observed thatetabolism 12, 456–466, November 3, 2010 ª2010 Elsevier Inc. 457
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Allosteric Regulation of Muscle Glycogen Synthaseseveral other mutants including single R582A, R582E, R586A,
R586E, R586A, and double R582A/R586A and R582E/R586E
mutants were also resistant to G6P (Figure 1B). However, the
R582E/R586E mutant displayed markedly reduced cellular
expression, and single R582E, R586E, and double R582A/
R586A mutants had 3-fold higher basal activity compared to
wild-type when assayed in the absence of G6P. We noticed
that the expression of glycogenin was reduced (e.g., R580A,
R580E, R586E) and gel mobility increased (e.g., R582E, R586E)
when particular GS mutants were cotransfected (Figure 1B).
We are unable to provide an accurate molecular explanation for
these alterations in glycogenin. We speculate that certain amino
acid substitutions may destabilize the interaction between GS
and glycogenin, resulting in reduced expression of both enzymes
(e.g., R580, R580E, R582E/R586E, R579A/R580A/R582A). Alter-
natively, amino acid substitution may have caused a change in
intrinsic activity/conformational change in the GS/glycogenin
complex, resulting in undefined posttranslational modifications
(e.g., glycosylation, phosphorylation) of glycogenin by an uniden-
tified mechanism(s). Among the mutants analyzed, only two
single-point mutants (R582A and R586A) retained normal levels
of expression (soluble) and catalytic activity (in the absence of
G6P) relative to the wild-type enzyme (Figure 1B). While a trace
amount of wild-type and mutant GS, as well as glycogenin, was
found in the particulate fraction of cell lysates, this also occurred
at similar levels (data not shown).We then examined if thesepoint
mutants (R582AandR586A) possessed normal phospho-depen-
dent activity. Since GS proteins overexpressed in HEK293 cells
were highly phosphorylated, we determined if R582A and
R586A mutants could be activated to the same degree as wild-
type by dephosphorylation in vitro. Purified wild-type, R582A,
R586A, and R582A/R586A GS mutants were incubated in the
presence of type 1 protein phosphatase (PP1) g. Wild-type GS
was efficiently dephosphorylated by PP1g, as evidenced by
faster gel mobility (Figure 1C), complete loss of immunoreactivity
to a phospho-specific GS antibody (data not shown), and the fact
that catalytic activity of the dephosphorylated enzyme was no
longer dependent on G6P (basal activity equivalent to G6P-satu-
rated activity) (Figure 1C). These effects were blocked by the
PP1 inhibitormicrocystin-LR (Figure1C).Notably,PP1gpromoted
a robust activation of G6P-resistant R582A and R586A mutants
with or without G6P close to the levels observed in wild-type,
whichwasassociatedwithamarkeddephosphorylationas judged
by gel mobility shift of total GS (Figure 1C) and staining with phos-
pho-specific antibodies (data not shown). Catalytic activity of the
doubleR582A/R586Amutantwasalso increasedbyPP1g-depen-
dent dephosphorylation, although amarkedly higher activity in the
absence ofG6P compared towild-typewas observed (Figures 1C
and 1A). Taken together, we have identified key Arg residues that
are essential for the allosteric activation of GS by G6P. The single
residues, Arg582 and Arg586, can be substituted for alanine to
generate mutant enzymes that are completely resistant to G6P
yet retain normal cellular expression and phospho-dependent
activity when expressed in HEK293 cells.
Generation and Characterization of G6P-Insensitive
GS Knockin Mice
To explore the physiological roles that allosteric activation of
GS by G6P might play in muscle glycogen metabolism458 Cell Metabolism 12, 456–466, November 3, 2010 ª2010 Elsevierin vivo, a knockin mouse was generated in which the codon
for arginine 582 of GYS1 (muscle isoform) was modified to
encode alanine (Figures 2A–2C). When the litters from
GS+/R582A breeding pairs were genotyped, we observed that
GSR582A/R582A mice were born at a slightly lower rate (18.4%)
than the expected normal Mendelian frequency (25%). Regard-
less, GSR582A/R582A knockin mice displayed no overt pheno-
type, and growth curves from 5 to 18 weeks of age in both
males and females indicated that these animals were of normal
size and weight (see Figure S1A available online). Likewise,
GSR582A/R582A knockin mice consumed a similar amount of
food compared to the wild-type (Figure S1B).
We determined if expression of mutant R582A GS in
GSR582A/R582A animals was comparable to wild-type GS in
several tissues. Immunoblot analysis revealed that there was
no difference in the levels of muscle GS between wild-type
and GSR582A/R582A knockin mice in various skeletal muscles
and other tissues (Figure 2D). We also observed that >98%
of GS protein in muscle lysates from wild-type and
GSR582A/R582A knockin mice was recovered in the soluble frac-
tion (supernatant after centrifugation at 3600 3 g for 5 min) and
the amount of GS protein detected in the pellet was similar
between these two genotypes (data not shown). We confirmed
there was no compensatory expression of the liver GS isoform
in tissues of GSR582A/R582A mice, as it was expressed at
a similar level in the liver of wild-type and GSR582A/R582A
animals and was undetectable in muscles in both wild-type
and GSR582A/R582A mice (Figure 2D). We next tested the effect
of G6P on GS activity in wild-type, GS+/R582A, and
GSR582A/R582A mice. As shown in Figure 2E, although G6P
robustly activated GS in muscle extracts derived from wild-
type animals, there was a complete loss of GS activation by
G6P at submaximal (0.3 mM) and saturating (12 mM) concen-
trations in extracts from GSR582A/R582A mice. G6P-stimulated
GS activity in muscle lysates from GS+/R582A animals was
reduced by more than 50% compared to wild-type (75%),
suggesting that the mutant enzyme exerts a dominant-negative
effect on wild-type GS. The G6P-independent activity (0 mM)
was comparable in all three genotypes.
Insulin Signaling and Phospho-Dependent GS Activation
Are Normal in GSR582A/R582A Mice
We next examined the regulation of phospho-dependent GS
activity by insulin in GSR582A/R582A knockin animals. Insulin injec-
tion robustly stimulated PKB phosphorylation and activity to the
same extent in wild-type, GS+/R582A, and GSR582A/R582A animals
(Figures 3A and 3B). PKB reduces the activity of GSK3a/b by
phosphorylation of inhibitory serine residues (S21/S9), which
was induced by insulin to a similar extent across all three geno-
types (Figure 3B). Using phospho-specific antibodies directed
against GSK3-target sites on GS (Ser641/Ser645), we
found that insulin promoted a marked dephosphorylation that
was similar in the muscles of the wild-type, GS+/R582A, and
GSR582A/R582A animals (Figure 3D). There was no significant
difference in phospho-dependent GS activity (measured in the
absence of G6P) for the three genotypes, and insulin injection
resulted in an 2-fold activation (Figure 3C). These results
demonstrate that insulin-mediated phospho-dependent GS
activation is normally maintained in GS knockin mice.Inc.
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Figure 2. Targeting Strategy Employed to
Generate GYS1 R582A Knockin Mutation
and Tissue Expression and Activity of GS
in GSR582A/R582A Knockin and Wild-Type
Mice
(A) Diagram showing the endogenousGYS1 allele,
the targeting knockin construct, the targeted allele
with the neomycin selection cassette (NEO) still
present, and the targeted allele with the NEO
removed by Flp recombinase. The gray boxes
represent exons (6–11), and the gray triangles
represent the FRT sites. The knockin allele con-
taining the Arg582Ala mutation in exon 14 is illus-
trated as a black rectangle.
(B) Genomic DNA isolated from the targeted
embryonic stemcells from the indicated genotypes
was digested with PstI and subjected to Southern
blot analysis with the corresponding DNA probes
(red boxes). The endogenous wild-type allele
generates a 17.9 kb fragment with both 50 and 30
probes, while the targeted knockin allele gives
rise toa8.7 kb fragmentwith the50 probe (left panel)
anda9.4 kb fragmentwith the30 probe (rightpanel).
(C) Genomic DNA isolated from mouse ear biop-
sies was subjected to PCR analysis with the
primer pairs, P1 and P2. The wild-type allele
produces a 172 bp DNA fragment, while the
knockin allele produces a 277 bp fragment.
(D) Equal amounts of extracts from skeletal
muscle (various), heart, and liver isolated from
the indicated genotypes were immunoblotted
with total muscle or total liver GS isoform-specific
antibodies. GAPDH was immunoblotted as
a loading control. Results are representative of
two independent experiments performed with
tissues from four mice.
(E) Gastrocnemius muscle from the indicated
genotypes was removed and freeze dried, and
extracts were prepared. GS activity was
measured in the absence and presence of a range
of G6P concentrations. Results are representative
of two independent experiments (n = 8/group).
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in Glycogen Synthesis In Vivo
We next sought to determine the role that allosteric activation of
GS by G6P plays in muscle glycogen synthesis. The rate of
glycogen synthesis in isolated skeletal muscle was measured
by monitoring incorporation of [14C]-glucose into endogenous
glycogen particles. Soleus muscle, containing predominantly
slow twitch-oxidative fibers, or extensor digitorum longus (EDL)
muscle, containing predominantly fast twitch-glycolytic fibers,
was isolated and incubated in the presence of 5.5 mM glucose
with or without insulin. In the absence of insulin, glycogenCell Metabolism 12, 456–466,synthesis in both muscle types was
reduced by 20%–30% in GS+/R582A
and 70% in the GSR582A/R582A mice
when compared to wild-type animals
(Figures 4A and 4B). Insulin stimulated
glycogen synthesis by 4- and 2-fold in
soleus (Figure 4A) and EDL (Figure 4B),
respectively, which was reduced 50%
in GS+/R582A mice and by 80% in bothmuscle types isolated from GSR582A/R582A mice compared to
wild-type. We next measured glycogen concentration in muscle
tissue. We found a robust decrease (50%) and an intermediate
(20%–30%) reduction in glycogen content in muscle derived
from GSR582A/R582A and GS+/R582A knockin mice, respectively,
under both fasted and fed conditions (Figure 4C and Figures
S2A and S2B). We observed that the levels of liver glycogen
were comparable between wild-type and knockin animals in
fasted and fed states (Figure 4D). In order to check if an enhanced
rate of glycogen degradation contributed to the reduced muscle
glycogen content observed in GS+/R582A and GSR582A/R582ANovember 3, 2010 ª2010 Elsevier Inc. 459
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Figure 3. Analysis of Insulin Signaling and Phospho-Dependent GS
Activity in GSR582A/R582A Mice and Wild-Type Mice
The indicated mice were fasted overnight and injected intraperitoneally with
insulin or vehicle (saline) under anesthesia. After 40 min, gastrocnemius
muscle was isolated, and tissue homogenates were assayed as follows.
(A) PKB kinase activity was measured in immunoprecipitates as described in
the Supplemental Experimental Procedures. The assay was performed in
duplicate (n = 4–6/group).
(B) PKB and GSK3a/b expression and phosphorylation were assessed by
immunoblotting with the indicated antibodies. Results are representative of
two independent experiments performed with tissues from four mice.
(C) GS activity in the absence of G6P was assayed. The assay was performed
in duplicate and the data shown are representative of two independent exper-
iments (n = 4–6/group).
(D) Total and phosphorylated GS were assessed by immunoblotting with the
indicated antibodies.
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Allosteric Regulation of Muscle Glycogen Synthaseknockin mice, we measured the activity of glycogen phosphory-
lase, a rate-limiting enzyme in glycogen breakdown. Phosphory-
lase activity in resting and insulin-stimulatedmuscles was similar
between wild-type and GS knockin mice (Figure 4E). Consistent
with this observation, phosphorylation at Ser15, a key regulatory
residue, was unchanged in the different genotypes in both basal
and insulin-stimulated states (Figure 4E).
To determine if the residual increase in muscle glycogen
synthesis in response to insulin observed in GSR582A/R582A mice460 Cell Metabolism 12, 456–466, November 3, 2010 ª2010 Elsevieris due to dephosphorylation of GS via GSK3 inactivation, we
have generated triple knockin mice that carry mutations in GS
(GSR582A/R582A) and GSK3a and -b (GSK3a/bS21A/S21A/S9A/S9A).
The triple knockinmice were viable, of normal size, and exhibited
no overt phenotype. Immunoblot analysis showed that insulin
failed to promote significant dephosphorylation of GS at Ser641
in muscles from the triple knockin mice (Figure S2E), consistent
with our previous findings in GSK3a/bS21A/S21A/S9A/S9A mice
(McManus et al., 2005). These mice displayed an additional
10% decrease in insulin-stimulated glycogen synthesis
compared to GSR582A/R582A mice in insulin-stimulated glycogen
synthesis compared to GSR582A/R582A mice, although there re-
mained a significant increase in glycogen synthesis upon insulin
treatment (Figure 4F).
Reduced Glycogenic Activity Results in an Increased
Glucose Flux through the Glycolytic Pathway
To investigate if the reduction in glycogen synthesis observed in
muscles from GSR582A/R582A mice was due in part to impaired
glucose transport activity, we measured 2-deoxyglucose uptake
in isolated muscles ex vivo. We observed no difference in resting
glucose uptake between wild-type and GS knockin animals, and
insulin stimulated glucose uptake by 4-fold and 1.5-fold in
soleus (Figure 5A) and EDL (Figure 5B), respectively, in all geno-
types. Immunoblot analysis confirmed that neither GLUT1 nor
GLUT4 protein levels were altered in muscles from GSR582A/R582A
mice (Figure 5G). Resting as well as insulin-stimulated G6P levels
in soleus muscles from GSR582A/R582A mice were higher (2- and
2.5-fold, respectively) than those from wild-type mice
(Figure 5C). UDP-glucose levels in restingmuscleswerenot signif-
icantly different between GSR582A/R582A and wild-type mice,
whereas insulin robustly reduced (2-fold) UDP-glucose levels in
the soleus of wild-type mice alone and was without effect on
GSR582A/R582A animals (Figure 5D). We measured the levels of
hexokinase II and UDP-glucose pyrophosphorylase in muscle
extracts and confirmed that expression of both enzymes was
unchanged in themuscle of GSR582A/R582Amice (Figure 5G). Since
glycogen synthesis was profoundly reduced in the muscles of
GSR582A/R582A animals, we hypothesized that glycolytic utilization
of glucose would be enhanced in these muscles. Soleus muscle
was incubated in the presence of 5.5 mM glucose containing
[5-3H]-glucose inKRBwith orwithout insulin. The rate of glycolysis
was monitored by measuring [3H] H2O released from the muscle
into the incubation medium, and glycogen synthesis was as-
sessed by monitoring [5-3H] glucose incorporation into glycogen
(Figure 5E). The rate of glycolysis in both resting and insulin-stim-
ulated muscles was robustly increased (2.5-fold) in
GSR582A/R582Amice relative to thatofwild-typeanimals.Consistent
with this observation, lactate release was also higher in
GSR582A/R582A muscle in both basal and insulin-stimulated condi-
tions relative to wild-type muscle (Figure 5F).
GSR582A/R582AMice Display Normal Whole-Body Glucose
Disposal and Insulin Sensitivity
We investigated if reduced muscle glycogen synthesis and
elevated intramuscular G6P levels would affect whole-body
glucose homeostasis in GSR582A/R582A knockin mice. As illus-
trated in Figures 6A and 6B, there was no difference in blood
glucose and plasma insulin levels from overnight fasted orInc.
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Figure 4. Analysis of Muscle Glycogen
Metabolism in GSR582A/R582A Knockin and
Wild-Type Mice
(A–D) Soleus or EDL muscles were isolated from
the indicated mice following overnight fast and
incubated in KRB buffer in the presence or
absence of 100 nM insulin. Glycogen synthesis in
soleus (A) and EDL (B) wasmeasured as described
in the Supplemental Information. *p < 0.05 basal
versus insulin within each genotype; (a) p < 0.05
versus WT (basal); (b) p < 0.05 versus +/R582A
(basal); (c) p < 0.05 versus WT (insulin); (d) p <
0.05 versus +/R582A (insulin) (n = 5–7/group).
(C andD) The indicatedmicewere fasted overnight
or fed ad libitum and muscle (gastrocnemius, C)
and liver (D) glycogen content was assessed.
*p < 0.05 WT (Fast) versus other genotypes (Fed);
#p < 0.05 WT (Fed) versus other genotypes (Fed).
(n = 5–7/group) (see also Figure S2).
(E) The indicated mice were fasted overnight and
injected intraperitoneally with insulin or saline
(basal) under anesthesia. After 40 min, gastrocne-
mius muscle was removed, snap frozen, and
processed to generate tissue extracts. Phosphor-
ylase activity was measured as described in the
Supplemental Experimental Procedures. Expres-
sion and phosphorylation of phosphorylase were
assessed by immunoblotting muscle lysates with
the indicated antibodies. (n = 4–5/group).
(F) The rate of glycogen synthesis in resting and
insulin-stimulated EDL muscles from the indicated
genotypes was measured ex vivo. Statistical anal-
ysis (ANOVA) was performed to reveal the differ-
ence between GSR582A/R582A and triple knockin
animals. *p < 0.05 basal versus insulin within
each genotype; (b) p < 0.05 versus GSR582A/R582A
(insulin). (n = 6–8/group).
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Allosteric Regulation of Muscle Glycogen Synthaserandomly fed animals between wild-type and GSR582A/R582A
knockin mice. We next performed glucose tolerance tests and
found thatGSR582A/R582A knockinmicewere able to dispose of in-
jected glucose at the same rate compared to their wild-type litter-
mates in both males (Figure 6C) and females (data not shown).
Similarly, insulin tolerance tests revealed an identical profile of
insulin-induced hypoglycemia and recovery over the time period
tested in wild-type and GSR582A/R582A knockin mice (Figure 6D).
To further investigate the insulin sensitivity of GSR582A/R582A
knockin mice in a more physiological context, we performed
euglycaemic-hyperinsulinaemic clamps, amethod that is consid-
ered thegold standard for assessingwholebodyglucosehomeo-
stasis in vivo. GSR582A/R582A knockinmice displayed nomodifica-
tion in whole-body glucosemetabolism judged by similar rates of
glucose infusion and disappearance during the insulin clamp
(Figures 6E and 6F and Figure S3).
DISCUSSION
GS is an enzyme of historical importance, as it was the first
example of an intracellular target for insulin (Villar-Palasi andCell MLarner, 1960) and is also classically used as an example of
enzymes that are controlled via allosteric and covalent mecha-
nisms in cells. Kinetic properties of the differentially phosphory-
lated forms of GS in cell-free assays have been extensively
documented since 1959 (Leloir et al., 1959; Roach, 2002), and
several transgenic mouse studies suggest physiological signifi-
cance of both allosteric and covalent regulation of GS in
glycogen accumulation in intact skeletal muscle tissue (reviewed
in Lawrence and Roach, 1997). However, the relative importance
of these two regulatory mechanisms, particularly the contribu-
tion of allosteric regulation to the control of GS and glycogen
storage in muscle, is not established, mainly due to the complex
interplay between multiple phosphorylation sites and allosteric
effectors and the absence of robust experimental tools (e.g.,
cell-based assays and genetic animal models). Identification of
key residues involved in the allosteric regulation of GS by G6P
(Figure 1 and Pederson et al., 2000) and generation of the
GSR582A/R582A knockin mouse enabled us to overcome various
inherent problems (discussed in Bouskila et al., 2008), and
here we provide compelling evidence that allosteric activation
of GS is the primary mechanism by which insulin promotesetabolism 12, 456–466, November 3, 2010 ª2010 Elsevier Inc. 461
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Figure 5. Analysis of Muscle Glucose Utili-
zation in GSR582A/R582A Knockin and Wild-
Type Mice
Soleus or EDL muscles were isolated from the
indicated genotypes following overnight fast and
incubated in KRB buffer in the presence or
absence of 100 nM insulin.
(A and B) 2-deoxyglucose uptake in soleus (A) or
EDL (B) wasmeasured as described in the Supple-
mental Experimental Procedures. *p < 0.05 basal
versus insulin within each genotype; (n = 5–7/
group).
(C–E) Isolated soleus muscle was incubated in
KRB buffer containing 5.5 mM glucose for 40 min
with or without 100 nM insulin. Muscle G6P (C)
and UDP-glucose (D) levels and lactate release
(E) were measured as described in the Supple-
mental Information.
(F) Isolated soleus was incubated in KRB buffer
with 5.5 mM glucose containing [5-3H]-glucose
for 40 min in the presence or absence of 100 nM
insulin. Glucose utilization by glycolysis and glyco-
genesis was assessed by measuring [3H]-H2O
accumulation in the incubation buffer and [3H]-
glucose incorporation into glycogen, respectively,
as described in the Experimental Procedures.
*p < 0.05 basal versus insulin within each geno-
type; (a) p < 0.05 versus WT (basal); (b) p < 0.05
versus WT (insulin). (n = 3–4/group).
(G) The indicated mice were fasted overnight, and
gastrocnemius muscles from saline- or insulin-in-
jected (i.p., 150 mU/g body weight, 40 min) ani-
mals were removed and tissue extracts generated.
The expression of GLUT1, GLUT4, hexokinase II,
and UDP-glucose pyrophosphorylase (UDPG-
PPL) was assessed inmuscle extracts by immuno-
blotting with the indicated antibodies. Four to five
samples for each condition from the indicated
mice were analyzed, and representative blots are
shown.
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Allosteric Regulation of Muscle Glycogen Synthaseglycogen synthesis upon incorporation of glucose into muscle
cells. Analysis of triple GSR582A/R582A/GSK3a/bS21A/S21A/S9A/S9A
knockin mice, in which both allosteric- and phospho-dependent
activation of GS by insulin is prevented, complemented the
results obtained from individual GSR582A/R582A (current study)
and GSK3a/bS21A/S21A/S9A/S9A (Bouskila et al., 2008; McManus
et al., 2005) knockinmice.We observed amodest, but significant
decrease (10%) in insulin-stimulated glycogen synthesis in the
muscle of the triple GSR582A/R582A/GSK3a/bS21A/S21A/S9A/S9A
knockin compared to that of GSR582A/R582A mice (Figure 4F).
Therefore, dephosphorylation of GS as occurs with insulin is
likely to play a ‘‘fine-tuning’’ role for GS by promoting changes
in enzyme kinetic properties, which would be expected to462 Cell Metabolism 12, 456–466, November 3, 2010 ª2010 Elsevier Inc.enhance the affinity for the substrate
UDP-glucose and also sensitivity to G6P
(Friedman and Larner, 1963; Jensen and
Lai, 2009). Whether G6P-bound/dephos-
phorylated GS proteins change localiza-
tion for efficient glycogen formation
would be an interesting subject to explore
in the future. The mechanism underlyingthe residual increase in glycogen synthesis in response to insulin
in triple GSR582A/R582A/GSK3a/bS21A/S21A/S9A/S9A knockin mice is
unclear. There was no detectable expression of the liver GS iso-
form (GYS2) in themuscle of GSR582A/R582A mice (Figure 2D), and
it is unlikely that an alternative GS-like enzyme catalyzes the
formation of glycogen, as muscle GS-deficient animals display
a loss of glycogen (Pederson et al., 2004). Although it would be
reasonable to assume that elevated UDP-glucose arising from
elevated insulin-stimulated glucose uptake would increase
glycogen synthesis by mass action, results from our work and
others are not sufficient to draw this conclusion. An increase in
the levels of G6P would be expected to increase concentrations
of downstream intermediates by mass action in the glycogen
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Figure 6. Glucose Tolerance, Insulin
Sensitivity, and Plasma Insulin Levels in
GSR582A/R582A Knockin and Wild-Type Mice
(A and B) Approximately equal numbers of 2- to
3-month-old male and female mice from indicated
genotypes (n = 6–7 animals) were fasted overnight
(Fasted) or fed ad libitum (Fed), and blood glucose
and plasma insulin levels were determined.
(C and D) Blood glucose concentration in 2- to 3-
month-old male GSR582A/R582A knockin and wild-
type mice was measured at the indicated times
following intraperitoneal administration of 2 mg/g
glucose following overnight fast or 0.75 mU/g
intraperitoneal insulin injection following 4 hr food
removal (n = 7–9 animals/genotype).
(E and F) A euglycaemic-hyperinsulinaemic clamp
study was performed as described in the Supple-
mental Experimental Procedures using four male
mice from each genotype (4 months old). The
clamp study started with a bolus of insulin
(100 mU/kg), followed by continuous insulin infu-
sion (3.5 mU/kg/min). A variable amount of
12.5% glucose solution was infused to maintain
euglycaemia (5 mmol/l) (E and Figure S3) during
a 90 min clamp, and whole-body glucose disposal
prior to and at the end of insulin infusionwas calcu-
lated (F) (n = 4 animals/genotype). Steady-state-
specific activities for 14C-glucose during both the
basal and hyperinsulinaemic period were achieved
(data not shown).
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Allosteric Regulation of Muscle Glycogen Synthasesynthesis pathway. In contrast, we (Figure 5D) and others (Rey-
nolds et al., 2005) observed that UDP-glucose levels were
reduced in muscles from wild-type animals with insulin, most
likely because a sufficient increase in G6P as well as insulin-
mediated dephosphorylation would activate GS, thereby
elevating the rate of UDP-glucose utilization. Our finding that
there was no decrease in UDP-glucose levels with insulin in the
muscles of GSR582A/R582A mice correlates with the markedly
reduced activity of muscle GS in these animals. Of note,
a previous work reported that the overexpression of UDP-
glucose pyrophosphorylase and an associated increase in the
levels of UDP-glucose do not affect glycogen synthesis in resting
and insulin-stimulated mouse skeletal muscles (Reynolds et al.,
2005). Finally, although it was not significant, there was a trend
for a reduction in GS phosphorylation (Ser641) in muscles from
the triple knockin mice in response to insulin (Figure S2E), and
we cannot completely rule out the possibility that insulin caused
GSK3-independent activation of GS (e.g., PP1-dependent) as
a compensatory mechanism.
We observed some dissociation between the reduction of
glycogen synthesis (70%–80%) measured in resting andCell Metabolism 12, 456–466,insulin-stimulated muscles ex vivo
(Figures 4A and 4B) and steady-state
muscle glycogen content (50%) in
overnight fasted or randomly fed
GSR582A/R582A mice compared to those
of wild-type animals (Figure 4C). There
are several possible explanations. First,
it is possible that insulin-independent
activation of GS contributes to glycogensynthesis and maintains glycogen levels in skeletal muscle
in vivo. It is well known that muscle contraction robustly stimu-
lates GS in order to rapidly restore glycogen content following
its breakdown by the action of phosphorylase for energy supply.
This occurs via dephosphorylation of GS, but in a PKB/GSK3-
independent (McManus et al., 2005) and PP1-dependent
manner (Aschenbach et al., 2001). Second, a reduced capacity
to synthesize muscle glycogen in GS knockin mice may have
led to metabolic adaptations resulting in the muscles of these
animals being more efficient at utilizing extracellular glucose
and/or fatty acids as substrates for energy production during
physical activity, producing a glycogen sparing effect (Pederson
et al., 2005). Interestingly, we observed a shift of glucose utiliza-
tion toward glycolysis in the muscles of GS knockin animals
(Figures 5E and 5F). It would be of interest to investigate if oxida-
tion of glucose and fatty acids is increased in muscles of
GSR582A/R582A mice during exercise. Third, given that steady-
state levels of glycogen are determined by the balance between
synthesis and degradation in vivo, it is possible that glycogenol-
ysis was inhibited as a result of some compensatory mechanism
in muscles of GSR582A/R582A knockin mice to avoid a profoundNovember 3, 2010 ª2010 Elsevier Inc. 463
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Allosteric Regulation of Muscle Glycogen Synthasedepletion of glycogen. We showed that the activity of glycogen
phosphorylase in muscle lysate was similar between the GS
knockin and wild-type animals (Figure 4E). However, like GS,
muscle phosphorylase activity is coordinately regulated by
phosphorylation and allosteric stimulators (e.g., AMP) and inhib-
itors (e.g., ATP, G6P) (Barford et al., 1991), and the cell-free
assay is largely a measure of the phospho-dependent activity.
Therefore, we cannot rule out the possibility that elevated levels
of G6P allosterically inhibited muscle phosphorylase in vivo. It is
unlikely that cellular levels of AMP and ATP were altered in
resting muscle of GS knockin mice, as activity of the AMP-acti-
vated protein kinase, which is regulated by changes in AMP:ATP
ratio (Hardie and Sakamoto, 2006), was unchanged (Figures S2C
and S2D). To investigate the inhibitory effect of G6P on muscle
phosphorylase and glycogenmetabolism in vivo, it will be neces-
sary to generate G6P-insensitive phosphorylase knockin
animals.
Glycogen synthesis is considered to be of major importance
for glucose homeostasis, as muscle with an impaired ability to
synthesize glycogen is proposed to attenuate its ability to re-
move glucose from the circulation, thereby causing insulin resis-
tance and type 2 diabetes. This is based on the assumption that
impaired glycogenic activity would be expected to promote
accumulation of intracellular G6P levels, which led to the inhibi-
tion of hexokinase, thereby reducing the rate of glucose trans-
port (Shulman, 2000). Consistent with this notion, we observed
that G6P levels are significantly elevated in muscle from GS
knockin compared to that from wild-type mice (Figure 5C). We
showed that resting as well as insulin-stimulated glucose trans-
port, assessed by [3H]-2-deoxyglucose uptake, was comparable
in isolated soleus and EDL muscles from GS knockin relative to
those of wild-type animals (Figure 5A). Although this confirmed
that there was no impairment in glucose transport activity in
the GS knockin muscles, whether elevated levels of G6P would
affect glucose transport under more physiological conditions
(e.g., 5–8 mM glucose) could not be addressed under these
experimental conditions (no glucose and 1 mM 2-deoxyglucose
in the transport buffer). Although 2-deoxyglucose uptake accu-
rately reflects glucose transport activity (Hansen et al., 1994),
its intracellular accumulation does not promote feedback inhibi-
tion of muscle hexokinase. A previous study showed that in cell-
free assays, G6P inhibits hexokinase by 80% at a concentration
of 0.5mM inmuscle homogenates, whereas even at a concentra-
tion of 30 mM, 2-deoxyglucose-6-phosphate fails to inhibit the
enzyme by 80% (Hansen et al., 1994). However, it should be
noted that when isolated soleus was incubated under euglycae-
mic conditions (5.5 mM glucose) ex vivo, glucose utilization, as
judged by the sum of glycogen synthesis and glycolysis, was
not reduced in knockin muscles (Figure 5E), suggesting that
glucose transport was not significantly inhibited. Whether
sustained accumulation of G6P occurs under physiological
conditions (e.g., following glucose ingestion) in vivo would be
interesting, and kinetic analysis of muscleG6P using noninvasive
nuclear magnetic resonance analysis can potentially shed light
on this. Nonetheless, our GSR582A/R582A knockin mouse model
provides a unique opportunity to test if reduced glycogenic
activity impairs whole-body glucose homeostasis. We demon-
strate that a drastically reduced rate of muscle glycogen
synthesis does not necessarily cause impaired whole-body464 Cell Metabolism 12, 456–466, November 3, 2010 ª2010 Elsevierglucose disposal. This is at least in part consistent with a study
employing muscle GS-deficient mice that lack glycogen in skel-
etal and cardiac muscles (Pederson et al., 2005). These mice
showed normal blood glucose levels in fasted and fed states
and of note they disposed of glucose more effectively than
wild-type animals. The mechanism by which GS null mice
showed improved clearance of blood glucose was not clear,
although the authors speculated that it might be due to sustained
elevation of serum insulin in the GS-deficient animals during
glucose tolerance tests. The GS null mice were leaner and
partially protected against the insulin resistance induced by
high-fat-diet feeding. This could be explained by the fact that
GS knockout mice had a higher proportion of oxidative fibers
with increased phosphorylation of AMPK and ACC, which indi-
cated enhanced capacity in the muscle of GS-deficient mice
for more efficient fatty acid and glucose oxidation. As described
above, AMPK activity and ACC phosphorylation were not altered
in resting muscles between wild-type and GS knockin mice (Fig-
ures S2C and S2D). Of note, whole-body insulin sensitivity of GS
null mice, judged by glucose infusion rate during a euglycaemic-
hyperinsulinaemic clamp, was no different from wild-type
animals. Insulin-induced glucose uptake into peripheral tissues
was decreased, whereas liver glycogen accumulation was
enhanced in the GS knockout mice, indicating muscle insulin
resistance. Results from the above study indicate that ablation
of muscle GS and a lack of glycogen produce complex meta-
bolic adaptations in various organs to maintain glucose homeo-
stasis. Moreover, the data need to be cautiously interpreted, as
the GS deficiency resulted in a cardiac developmental problem,
and only10% of the GS null mice survive birth (Pederson et al.,
2004). Because 90% of muscle GS knockout mice die shortly
after birth, one cannot rule out the possibility that the subset of
animals studied was adapted to dispose glucose normally
because of the presence of some factor that enabled their
survival (Pederson et al., 2005).
Since a reduced capacity to synthesize muscle glycogen did
not impair glucose disposal, one might question the importance
of muscle glycogen accumulation for blood glucose homeo-
stasis at least in the mouse and also wonder whether mice are
an appropriate model to study human metabolism. When ex-
pressed as a percentage of total body glycogen, glycogen
content in mouse skeletal muscle is only 10% of that in human
muscle (Kasuga et al., 2003). In addition, humans have 3- to
8-fold more muscle glycogen than that in liver, whereas fed
mice contain five to ten times more total glycogen in liver than
in skeletal muscle (Irimia et al., 2010). Therefore, the relative
contribution of muscle and hepatic glycogen in controlling
glucose homeostasis might be different between mice and hu-
mans with hepatic energy reserves of greater importance in
mice. Interestingly, some recent reports describing the clinical
and metabolic phenotypes of human subjects with mutations/
polymorphisms in genes involved in glycogen metabolism
suggest a critical role for muscle glycogen accumulation in
energy production during exercise, but not for glucose homeo-
stasis. Kollberg et al. have reported that human subjects carrying
a homozygous stopmutation in exon 11 in theGYS1 gene, which
is predicted to cause truncation of GS at Arg462, resulted in
a loss of GS proteins in both skeletal and heart muscles (Kollberg
et al., 2007). Muscle GS-deficient subjects exhibit reducedInc.
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Allosteric Regulation of Muscle Glycogen Synthaseexercise capacity with rapidmuscle fatigability most likely due to
an inability to utilize glycogen as an energy source for ATP gener-
ation during muscle contraction. However, they display a normal
blood glucose profile when challenged with an oral glucose load.
In addition, muscle glycogen depletion due to inactivation of gly-
cogenin-1, caused by biallelic mutations in GYG1, resulted in
muscle weakness and cardiac arrhythmia; however, the patient
exhibited normal glucose tolerance, and levels of fasting glucose
and glycated haemoglobin were also normal (Moslemi et al.,
2010). Taking our current results and previous findings together,
it can be argued that impaired glycogen synthesis as seen in type
2 diabetics may not be a primary cause of insulin resistance;
rather it is a consequence due to multiple defects in the insulin
signaling pathway, resulting in impaired glucose transport (Shul-
man, 2000). A reduced rate of glucose transport and concomi-
tant decrease in intramuscular accumulation of G6P would
attenuate glycogen synthesis via reduced allosteric activation
of GS. Therefore, glucose transport is the critical step for
insulin-stimulated glycogen synthesis, and suggests that muscle
glucose transport represents a more important therapeutic
target for insulin resistance and type 2 diabetes.
We propose that increased levels of intramuscular G6P via
glucose transport in response to insulin allosterically stimulate
GS, which drives it into glycogen as a feed-forward mechanism,
and this effect could be further enhanced when GS is dephos-
phorylated by inactivation of GSK3 (Patel et al., 2008), as this
makes GS more sensitive to G6P. This proposition is consistent
with the metabolic control theory proposed by Shulman and
Rothman (Shulman and Rothman, 1996). The interplay between
allosteric regulation and covalent phosphorylation allows GS to
detect small changes in the levels of G6P when elevated upon
insulin stimulation. This sophisticated enzyme control system
facilitates a sustained influx of glucose, which would prevent
a buildup of the levels of intermediates. There are many exam-
ples of metabolic enzymes that are coordinately regulated via
an interplay between allostery and phosphorylation, and eluci-
dating such interplay would be fundamental in understanding
the in vivo regulation of metabolic flux control.
EXPERIMENTAL PROCEDURES
Cell Culture, DNA Transfection, and Purification of GS
HEK293 cells were cultured using standard protocols and transfected with
20 ml of polyethylenimine (1 mg/ml) and 5–10 mg of plasmid DNAs per 10 cm
dish. Thirty-six hours following transfection, cells were washed twice with
ice-cold PBS and lysed in ice-cold lysis buffer. Lysates were clarified by centri-
fugation and the supernatant assayed for protein concentration using Bradford
reagent. Cell extracts (70–100 mg protein) generated from cotransfection of
untagged GS (wild-type or mutants) and GST-tagged glycogenin were incu-
bated with glutathione Sepharose for 1 hr at 4C and the resin washed twice
with lysis buffer containing 0.5 M NaCl and twice with buffer A (50 mM Tris-
HCl [pH 7.5], 0.1 mM EGTA). GST-glycogenin:GS complexes were eluted
with 20 mM reduced glutathione. The eluted proteins and BSA standards
were resolved on SDS-PAGE and stained with Coomassie blue R250. The
band corresponding to GS was scanned and the protein concentration esti-
mated by densitometric analysis using a LI-COR Odyssey imaging system.
Glycogen Synthase Activity
GS activity was measured by a modification of the method of Thomas et al.
(Thomas et al., 1968) and described in detail (Lai et al., 2007). Muscles were
freeze dried for 3 hr, and 2–3 mg tissue (dry weight) was homogenized
(1:400; dry tissue weight:volume) with a rotor-stator homogenizer (Polytron,Cell MKinematica AG) in ice-cold buffer containing 50 mM Tris-HCl (pH 7.8),
100 mM NaF, 10 mM EDTA. Homogenates were centrifuged for 5 min at
3600 3 g at 4C and GS activity measured in supernatants as follows: 20 ml
of supernatant was added to 40 ml assay buffer (25 mM Tris-HCl [pH 7.8],
50 mM NaF, 5 mM EDTA, 10 mg/ml glycogen, 1.5 mM UDP-glucose, and
0.5 mCi/ml D-[14C]-UDP-glucose) with 0, 0.3, and 12 mM G6P. Reactions
were incubated for 8 min at 37C and stopped by spotting 50 ml onto squares
of filter paper (Whatman ET-31) which were immediately immersed in ice-cold
66% ethanol and washed twice more in 66% ethanol. Dried filters were sub-
jected to scintillation counting.
Determination of Muscle Glucose Utilization
Muscle glycolytic rates were determined by the detritiation of [5-3H]-glucose
during the reactions catalyzed by triose phosphate isomerase and enolase.
The glucose tracer was dried using a Savant Speedvac concentrator to re-
move [3H] H2O accumulated during storage as a consequence of radiolysis.
Isolated soleus muscles were incubated in 2 ml Krebs-Ringer bicarbonate
(KRB) containing 5.5 mM glucose and 0.5 mCi.mmol [5-3H]-glucose for
40 min at 37C, gassed continuously with 95%/5% O2/CO2. Muscles were
snap-frozen in liquid nitrogen and processed for determination of [5-3H]
glucose incorporation into glycogen as described for [14C(U)]glucose. [3H]
H2O was isolated by borate complex ion exchange chromatography. Briefly,
aliquots (0.5 ml) of conditioned KRB were applied to 1 ml columns of
Dowex-1-borate and washed with 2 ml water to elute [3H] H2O. Glucose forms
a borate complex and is retained by the resin. Columns were regenerated with
0.5 M potassium tetraborate. [3H] H2O was determined by scintillation count-
ing and corrected for leakage of [5-3H]-glucose (typically less than 0.03%).
Statistical Analyses
Data are expressed as mean ± SEM. Statistical analysis was performed by
two-tailed Student’s t test or one-way ANOVA with Newman-Keuls multiple
comparison post hoc test. Differences between groups were considered as
statistically significant when p < 0.05.
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